Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Medrx, Last Fiscal Year's Net Income Loss Widens, Current period performance is undisclosed.
4586 Medrx Co.,Ltd. 【J-GAAP】
Earnings ReportMedrx Co.,Ltd. <4586> [TSE Growth] announced its financial results after the market closed on February 13th (15:30). The consolidated net loss for the fiscal year ended December 2025 expanded to a loss of 0.93 billion yen (compared to a loss of 0.80 billion yen in the previous period). The result was better than the previously estimated deficit of loss of 1.35 billion yen. This marks the nineteenth consecutive term of losses. Furthermore, the company did not disclose the performance outlook for the fiscal year ending December 2026.
In the most recent three-month period, from October to December (4Q), the consolidated net loss improved to a deficit of 0.16 billion yen (compared to a loss of 0.48 billion yen in the same period last year). The operating profit/loss margin improved from -20700.0% in the same period last year to -1990.0%.
Kabutan News
Actual Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2023 | 29 | -933 | -930 | -932 | -26.8 | 0 | Feb 9, 2024 | J-GAAP |
| Dec, 2024 | 257 | -793 | -755 | -806 | -18.6 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 128 | -941 | -937 | -937 | -17.4 | 0 | Feb 13, 2026 | J-GAAP |
| YoY | -50.2% | -18.7% | -24.1% | -16.3% | +6.0% |
Full Year Results vs. Previous Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2025 Guidance | 122 | -1,335 | -1,335 | -1,350 | -22.7 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 Results | 128 | -941 | -937 | -937 | -17.4 | 0 | Feb 13, 2026 | J-GAAP |
| Revision Rate | +4.9% | +29.5% | +29.8% | +30.6% | +23.3% |
Current Period Guidance
H1 Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Jan - Jun, 2025 | 18 | -609 | -623 | -629 | -12.8 | 0 | Aug 8, 2025 | J-GAAP |
| Jan - Jun, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Current Period Guidance
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Dec, 2024 | 257 | -793 | -755 | -806 | -18.6 | 0 | Feb 14, 2025 | J-GAAP |
| Dec, 2025 | 128 | -941 | -937 | -937 | -17.4 | 0 | Feb 13, 2026 | J-GAAP |
| Dec, 2026 Guidance | ー | ー | ー | ー | - | 0 | Feb 13, 2026 | J-GAAP |
| YoY | - | - | - | - | - |
Quarterly Results
| Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
|---|---|---|---|---|---|---|---|---|
| Oct - Dec, 2024 | 2 | -414 | -412 | -486 | -11.2 | -20,700.0 | Feb 14, 2025 | J-GAAP |
| Jan - Mar, 2025 | 2 | -419 | -422 | -429 | -9.0 | -20,950.0 | May 9, 2025 | J-GAAP |
| Apr - Jun, 2025 | 16 | -190 | -201 | -200 | -4.1 | -1,187.5 | Aug 8, 2025 | J-GAAP |
| Jul - Sep, 2025 | 100 | -133 | -134 | -140 | -2.7 | -133.0 | Nov 14, 2025 | J-GAAP |
| Oct - Dec, 2025 | 10 | -199 | -180 | -168 | -3.1 | -1,990.0 | Feb 13, 2026 | J-GAAP |
| YoY | +400.0% | +51.9% | +56.3% | +65.4% | +72.0% |
Related Articles
IID, First Half Ordinary Profit Decreases by 27%, Oct-Dec Ordinary Profit Decreases by 8%
Toho Zinc, Ordinary Profit Forecast for the Fiscal Year Revised Upward by 94%
Bridge Consulting, Oct-Dec (1Q) Ordinary Profit Increases by 15%
TAUNS Laboratories, First Half Ordinary Profit Decreases by 52%, Oct-Dec Ordinary Profit Decreases by 5%
Bushiroad, First Half Ordinary Profit Increases by 82%
GOKURAKUYU, Apr-Dec (Cumulative 3Q) Ordinary Profit Increases by 0.3%, Oct-Dec Ordinary Profit Decreases by 21%
REPRIORITY CORP, Oct-Dec (1Q) Ordinary Profit Decreases by 55%
General Oyster, Apr-Dec (Cumulative 3Q) Ordinary Profit Turns to Loss, Oct-Dec Ordinary Profit Decreases by 41%
Direct Marketing MiX, 30% Increase in Net Income for The Current Fiscal Year, Dividend Raised by 2.5 Yen
Billing System, 42% Increase in Ordinary Profit, Update Record High for Third Consecutive Term, Dividend Raised by 6.7 Yen